Simeprevir/Strong or Moderate CYP3A4 Inducers
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Bosentan, carbamazepine, dabrafenib, dexamethasone, enzalutamide, etravirine, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, and St. John's wort may speed up how quickly your liver processes simeprevir.
What might happen:
The amount of simeprevir in your blood may decrease and it may not work as well.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you have taken bosentan, carbamazepine, dabrafenib, dexamethasone, enzalutamide, etravirine, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, or St. John's wort in the previous two weeks, or if you stop taking any of these medicines. Your doctor may want to adjust your medicines.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Olysio (simeprevir) US prescribing information. Janssen Products, LP April, 2015.
2.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
3.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..